[Influence of intensive insulin therapy on the intestinal microcirculatory dysfunction in rats with sepsis].
OBJECTIVE
To explore the influence of intensive insulin therapy on the intestinal microcirculatory dysfunction of rats suffering from sepsis.


METHODS
The sepsis model of rat was reproduced by cecal ligation and puncture. Forty-eight male Sprague-Dawley (SD) rats were randomly divided into control group, sepsis group, and insulin treatment group (n =16 in each group). The intestinal tissue was harvested in the experimental groups before and 3, 6, 12 and 24 hours after insulin administration. Platelet activating factor (PAF), prostacyclin (PGI(2)) and thromboxane (TXA(2)) in the intestine were measured by radioimmunoassay.


RESULTS
The levels of PAF, PGI and TXA(2) were significantly elevated in sepsis group at 3 hours, and peaked at 6 hours, then decreased gradually. At each time point they were higher in sepsis group compared with that of control group (all P<0.05), especially TXA(2), which was more evident, while PGI(2)/TXA(2) ratio showed a lowering. In contrast, PAF, PGI(2) and TXA(2) were significantly decreased in insulin treatment group compared with the sepsis group, especially TXA(2), which was more evident ( all P<0.05), but PGI(2)/TXA(2) ratio showed an elevation.


CONCLUSIONS
Insulin plays an important role in amelioration of microcirculatory dysfunction in sepsis. Through improving the disorder of PGI(2)/TXA(2)system and antagonising the expression of PAF, insulin alleviates vasospasm, inhibits platelet aggregation and thrombosis, thus protecting the function of intestine.
Shi
Bin
B
Intensive Care Unit, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China.
Yin
Chao
C
Guo
Hong
H
Li
Bin
B
Liu
Li-ping
LP
D000818:Animals; D004195:Disease Models, Animal; D011464:Epoprostenol / Q000378:metabolism; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000503:physiopathology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D010972:Platelet Activating Factor / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D013928:Thromboxane A2 / Q000378:metabolism
D007328:Insulin; D010972:Platelet Activating Factor; D013928:Thromboxane A2; D011464:Epoprostenol